NCT02375581

Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer

A Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 130 (estimated)
• Sponsor: First People's Hospital of Hangzhou · Academic / Other
• Sex: All
• Age: 70 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To investigate the efficacy and toxicity of EGFR tyrosine-kinase inhibitor (Icotinib) with concurrent radiotherapy in older patients with esophageal cancer.

Detailed description

Older patients with esophageal cancer have been correlated with poor prognosis because of having little chance to receive aggressive local therapy, including surgery or concurrent chemoradiotherapy. EGFR is overexposed in most of the cases. In this phase II trial, the efficacy and toxicity of EGFR tyrosine-kinase inhibitor (Icotinib) with concurrent radiotherapy will be investigated in this setting.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	Icotinib	125mg, Po, TID during RT
RADIATION	Thoracic radiotherapy	involved-Field irradiaton without elective nodal irradiation

Timeline

• Start date: 2015-01-01
• Primary completion: 2017-12-01
• Completion: 2018-12-01
• First posted: 2015-03-02
• Last updated: 2016-03-22

Locations

1 site across 1 country: China